Atrial fibrillation is the most common abnormal heart rhythm and has tripled in prevalence of the last 50 years. Approximately 20% of patients with atrial fibrillation may not even know that they have the arrhythmia. This podcast episode will provide insight into the importance of undiagnosed atrial fibrillation and will give practical tips to the pharmacist interested in developing a screening program for identifying undiagnosed atrial fibrillation.
To learn more, visit www.ashpadvantage.com/nvaf
James S. Kalus, PharmD, FASHP, is Director of Pharmacy at Henry Ford Health System in Detroit, Michigan where he is responsible for planning, implementing, and managing all pharmacy services related to patient care including staff training and development, and pharmacy research. Dr. Kalus also serves as Program Director for the postgraduate year one (PGY1) residency at Henry Ford Hospital and is adjunct assistant professor of pharmacy and medicine at Wayne State University. In his research, Dr. Kalus has focused on cardiovascular disease, including the pathophysiology of atrial fibrillation (AF) occurring after cardiac surgery, novel strategies for the treatment and prevention of AF, practice-based research related to anticoagulation and implementation science related to clinical pharmacy services.
Devin Lavender, PharmD, BCPS, BCACP is Clinical Assistant Professor at the University of Georgia College of Pharmacy in Athens, Georgia where he practices in Ambulatory Care and chronic disease management at the Athens Community Based Outpatient Clinic affiliated with the Charlie Norwood VA Medical Center. Dr. Lavender obtained his PharmD degree from The University of Georgia College of Pharmacy. He completed a PGY1 Pharmacy Practice Residency at the Memphis VA Medical Center followed by a PGY2 Ambulatory Care Specialty Residency at the University of Georgia College of Pharmacy in conjunction with the Charlie Norwood VA Medical Center.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
More in this series
Provided by ASHP
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance